Belite Bio Announces Exercise of Warrants, Raises US $28.75 Million in Gross Proceeds
Belite Bio Announces Definitive Agreement for Exercise of Warrants SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) — Belite Bio, Inc (NASDAQ: BLTE) Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, has recently made waves with its announcement of a definitive agreement for the exercise of certain outstanding warrants. These warrants, originally issued in April…